Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab.

JHEP Rep · 2026 · PMC12936939 · PMID 41768078

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0700

boldest claim

The sentences

borderline significantp = 0.06so close (0.05 < p ≤ 0.1)

BCLC stage showed a borderline significant association with plasma GPC3 levels, with higher levels in stage C than in stage B (13.5 [0.0–51.8] vs. 0.0 [0.0–21.6] pg/ml; p = 0.06).

also in 11,409 other papers

did not reach statistical significancep = 0.07so close (0.05 < p ≤ 0.1)

H-score and IHC intensity did not reach statistical significance for OS ( p = 0.07 and p = 0.17, respectively).

also in 111,027 other papers

showed a trendno p-value reported

Cross-validated cut-offs were consistent across folds (median 9.0 pg/ml, range 9.0–10.6), and high plasma GPC3 levels in the test folds consistently showed a trend toward worse outcomes (PFS: median HR 1.58, range 1.17–3.87; OS: median HR 2.49, range 1.17–9.62).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.